Agi­lent to ex­pand port­fo­lio in cell anal­y­sis

BioSpectrum (Asia) - - Supplier News -

Agi­lent Tech­nolo­gies Inc. has signed a de­fin­i­tive agree­ment to ac­quire pri­vately-owned ACEA Bio­sciences Inc., a de­vel­oper of cut­ting-edge cell anal­y­sis in­stru­ments for life science re­search and clin­i­cal di­ag­nos­tics, for $250 mil­lion in cash. Since its in­cep­tion in

2002, ACEA has launched two ground-break­ing, highly dif­fer­en­ti­ated plat­forms. ACEA is rev­o­lu­tion­iz­ing the field of flow cy­tom­e­try with its high-per­for­mance, cus­tom­iz­a­ble line of NovoCyte bench­top flow cy­tome­ters. ACEA’s xCELLi­gence in­stru­ments en­able la­bel-free, real-time mon­i­tor­ing of cell growth, cell func­tion, and cel­lu­lar re­sponses to a va­ri­ety of treat­ments, pro­vid­ing sci­en­tists in­for­ma­tion­rich cel­lu­lar as­says.

ACEA in­stru­ments are used world­wide in both academia and in­dus­try across a wide range of life science ap­pli­ca­tions from ba­sic re­search to clin­i­cal di­ag­nos­tics in­clud­ing pre­clin­i­cal drug dis­cov­ery and de­vel­op­ment, tox­i­col­ogy & safety phar­ma­col­ogy, and var­i­ous dis­ease stud­ies. ACEA is head­quar­tered in San Diego and has a large man­u­fac­tur­ing and R&D foot­print in Hangzhou, China.

Newspapers in English

Newspapers from India

© PressReader. All rights reserved.